The Pfizer/BioNTech and Moderna mRNA vaccines were authorized for emergency use less than one year after the emergence of COVID-19, demonstrating the incredible development speed of the mRNA platform technology. However, while the versatility of the mRNA platform could allow for worldwide development of new vaccines, constraints including restricted intellectual property (IP), high cost of goods, raw material bottlenecks and lack of trained staff limit access to mRNA vaccines in low- and middle-income countries (LMICs).
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Acknowledgements
The mRNA working group is an internal strategic group composed of experts from CEPI (A.K., J.B., I.-K.Y., N.H., D.M. and G. Voss) and the Bill & Melinda Gates Foundation (P.-A. Gilbert, D. Lee, G. Sanyal and H. Kanzler). The authors thank M. Saville, M. Christodoulou and mRNA working group members for input to the article. J. Granerod Whitehouse is also thanked for writing support.
Competing Interests
CEPI is a funder of different vaccine platforms, including mRNA.
